<DOC>
	<DOCNO>NCT03098732</DOCNO>
	<brief_summary>The objective MEDIS study determine subject experience Acute Ischaemic Stroke due large vessel occlusion , treat IV tPA combine MED procedure great likelihood recanalisation 30-90 minute completion tPA infusion subject treat IV tPA ( plus sham device ) . Safety MED System Procedure evaluate incidence symptomatic PH-2 haemorrhagic transformation within 24 hour follow procedure . Lastly , health economics study conduct estimate health care cost treatment .</brief_summary>
	<brief_title>Magnetically Enhanced Diffusion Acute Ischaemic Stroke ( MEDIS ) Trial</brief_title>
	<detailed_description>The study global , multicentre prospective , randomise , single blind , blind endpoint study compare rate early recanalisation ( defined mAOL ) Acute Ischaemic Stroke ( AIS ) subject visible occlusion treat either IV tPA plus sham device IV tPA combination MED System procedure . The study population randomise 1:1 two arm : - A Sham Control Group ( SCG ) - Experimental Treatment Group ( ETG ) . The ETG receive IV tPA complete MED System procedure consist MED MicroBeads MED Workstation magnet procedure . The SCG receive MED MicroBeads MED Workstation activate Sham control . Subjects blind treatment arm . Stratification perform base upon baseline age location occlusion ( Middle Cerebral Artery segment M1 , M2 , Carotid Terminus ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Embolism Thrombosis</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Intracranial Embolism</mesh_term>
	<mesh_term>Infarction , Middle Cerebral Artery</mesh_term>
	<mesh_term>Intracranial Embolism Thrombosis</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Age ≥18 &lt; 85 2 . Clinical sign consistent acute ischaemic stroke 3 . Prestroke functional independence ( prestroke Modified Rankin Score ≤2 ) 4 . NIHSS 425 time randomisation 5 . Initiation IV tPA ( alteplase tissue Plasminogen Activator ) within locally approve time window stroke symptom onset ( onset time define last time subject witnessed baseline ) . 6 . Arterial Occlusive Lesion ( mAOL ≤1 ) M1 M2 segment MCA ( Middle Cerebral Artery ) carotid terminus confirm CT angiography . 7 . Subject able start MED procedure within 15 +10 minute ) tPA IV infusion , complete 60+15 minute MED procedure treatment . 8 . Subject subject 's legally authorised representative sign date Informed Consent Form accord country regulation , ethic committee , and/or Institutional Review Board requirement . 9 . It enrol Investigator 's designee 's opinion base upon knowledge Subject 's condition well feature MED device , Subject appropriate candidate stroke management utilizing MED . 1 . The subject likely receive intraarterial ( IA ) intervention . 2 . Standard exclusion thrombolysis accord approve label local institutional protocol . 3 . Female pregnant lactate positive pregnancy test time admission . 4 . Rapid neurological improvement prior study randomisation suggest resolution occlusion . 5 . Known hypersensitivity radiographic contrast agent . 6 . Known hypersensitivity ironbased agent polyethylene glycol . 7 . Known suspected symptomatic haemosiderosis haemochromatosis . 8 . Has previous exist cardiovascular condition result history heart block , tachybrady syndrome , symptomatic postural hypotension require medical intervention . 9 . Current participation participation last 4 week another investigational drug device treatment study . 10 . Life expectancy le 90 day due medical condition . 11 . Subject pre‐existing neurological psychiatric disease would confound neurological functional evaluation . 12 . Subject contraindication Magnetic Resonance Imaging ( MR ; example include , limited , implantable cardioverter defibrillator , pacemaker , clip coil aneurysm , neurostimulator ) . 13 . Subject recently ( within 30 day ) receive iron replacement therapy iron base MR contrast . 14 . Subject know suspected liver disease , include hepatitis and/or cirrhosis . Imaging 1 . Computed tomography ( CT ) MRI evidence haemorrhage presentation . 2 . Exclusion : Large core ischemia define NCCT ASPECTS 4 le . 3 . CT MRI evidence mass effect intra‐cranial tumour ( except small meningioma ) . 4 . CTA MRA ( CT MR Angiography ) evidence carotid dissection complete cervical carotid occlusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Ischemic</keyword>
	<keyword>Tissue Plasminogen Activator</keyword>
	<keyword>Thrombolysis</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cerebrovascular Disorders</keyword>
	<keyword>Fibrinolytic Agents</keyword>
	<keyword>Plasminogen</keyword>
</DOC>